The ability to diagnose breast cancer by studying human hair may sound a little out there, but Sydney company Fermiscan is about to finalise a validation trial of technology that will do just that.

The annual Lorne conferences begin this weekend. First up, protein structure and function, where we learn the tricks of the bacterial toy trade.

Sydney researchers have identified the components of telomerase, the enzyme associated with uncontrolled cell growth, and have come up with a nifty method for purifying it.

A collaboration between Agilent Technologies and the University of California at Davis (UCD) has developed a new way to characterise glycans in human breast milk.

The international Human Variome Project is up and running following a highly successful first meeting in Melbourne in June.

Following the resignation of CogState chief executive officer Peter Bick, Brad O'Connor has been promoted internally from chief financial officer to the CEO role.

The Australian Stock Exchange has created a market that attracts not only local biotechnology companies, but also gives opportunities to foreign companies that would be unable to attract capital in their own markets. Helen Schuller reports.

Australia's best-known and most venerable medical research institute, The Walter and Eliza Hall Institute of Medical Research in Parkville, Melbourne, celebrates its 90th anniversary this year. Graeme O'Neill interviewed the Hall's former director, Prof Sir Gustav Nossal, and his successor, Prof Suzanne Cory, about the institute's history and their view of science in Australia today.

Could 'farmer power' force Australian state governments to back down on their moratoria on GM crops? Graeme O'Neill reports.

Victorian treasurer and minister for innovation, John Brumby, has called on the federal government to lift its ban on somatic cell nuclear transfer (SCNT), otherwise known as therapeutic cloning.

Sydney anti-viral drug developer Narhex Life Sciences (ASX:NLS) has relocated its head office to Melbourne following the resignation of founder and managing director John Majewski.